v3.26.1
Collaborative and Other Relationships - Syndax (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 58 Months Ended
Sep. 30, 2021
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
License Agreements              
Long term equity investments   $ 104,387   $ 104,387   $ 104,387 $ 47,991 [1]
Research and development   516,950 $ 494,917 1,032,853 $ 932,196    
Cost of sales (including definite-lived intangible amortization)   $ 104,957 78,766 $ 209,480 151,954    
Investment in Syndax              
License Agreements              
Investment owned (in shares)   1,400,000   1,400,000   1,400,000  
Long term equity investments   $ 31,100   $ 31,100   $ 31,100 29,900
Gain (loss) on equity investments   (2,100) (4,200) 1,200 (5,500)    
Syndax              
License Agreements              
Upfront payment under license agreement           129,500  
Research and development   4,900 $ 5,300 10,300 $ 10,000    
Syndax | Axatilimab - Development Activities              
License Agreements              
Accrued and other liabilities   1,400   1,400   1,400 2,400
Syndax | Development and Regulatory Milestones | Maximum              
License Agreements              
Additional milestone payments under the license agreement   207,500   207,500   207,500  
Syndax | Commercialization Milestones | Maximum              
License Agreements              
Additional milestone payments under the license agreement   $ 225,000   $ 225,000   225,000  
Syndax | Incyte              
License Agreements              
Funding of future development costs   55.00% 55.00% 55.00% 55.00%    
United States | Syndax              
License Agreements              
Profit share percentage from co-commercialization efforts       50.00%      
Cost of sales (including definite-lived intangible amortization)   $ 20,200   $ 34,600      
United States | Syndax | Axatilimab - Commercialization Activities              
License Agreements              
Accrued and other liabilities   $ 26,500   $ 26,500   $ 26,500 $ 27,600
United States | Syndax | Syndax              
License Agreements              
Funding of future development costs 45.00%            
United States | Syndax | Incyte              
License Agreements              
Funding of future development costs 55.00%            
[1] The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited consolidated financial statements at that date.